Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

Detailed results from pivotal TALAPRO-3 study presented at ASCO 2026 and published in The New England Journal of Medicine ...

*Foster Sylvers, the former child star whose youthful voice and magnetic stage presence helped propel The Sylvers to national fame in the 1970s, has died. He was 64. His brother, Leon Sylvers III, ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Johnson & Johnson (JNJ) reported late-stage clinical trial results showing that adding its prostate cancer drug apalutamide to hormone therapy before and after surgery improved outcomes for men with ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We conducted a ...

Bayer Shares New Findings for NUBEQA for Cognitive Decline in Men with aPC Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial ...

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer.  | After winning a broader FDA label in metastatic castration-resistant prostate cancer, ...

Revolution Medicines' pan-RAS (on) inhibitor daraxonrasib has delivered a big result in pancreatic cancer, with a doubling in overall survival compared to chemotherapy in the highly anticipated ...